Vascular Effects of SGLT2i in Non-diabetic CKD

NCT07060417 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

FED

Sponsor class

Conditions

Non-diabetic Chronic Kidney Disease

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

VA Office of Research and Development